
Search
Selected Filters
Filter Results
Displaying 211–220 of 254 research results
-
Aug 2, 2016
Pixium Vision Reports Progress in Development of Two Advanced Bionic Retina Systems
Both approaches show strong, near-term potential for providing meaningful vision to people who are otherwise blind from retinal diseases such as retinitis pigmentosa and age-related macular degeneration (AMD).
-
Jul 21, 2016
Stem-Cell Therapy for Retinitis Pigmentosa Safe Thus Far in Early Human Study
The trial is one of the first-ever for a stem-cell-derived therapy for RP.
-
Jul 1, 2016
Dr. Weleber became the 10th recipient of the Foundation’s highest honor, named after FFB co-founder Lulie Gund, during the opening lunch of the VISIONS 2016 conference.
-
Jul 1, 2016
At VISIONS 2016, FFB’s national conference, the Foundation honored him with its Ed Gollob Board of Directors Award for breakthrough research conducted within the past year.
-
Jun 24, 2016
A Steady Hand in Saving Vision
Subretinal injection is the most common form of delivery for gene therapies currently in clinical trials.
-
Jun 6, 2016
Fighting Blindness Gets Sheepish
Researchers in Israel are developing a gene therapy for achromatopsia that may help both sheep and humans alike.
-
May 5, 2016
ARVO 2016: High-School Sophomore Finds Gene Mutation in Family with Choroideremia
Aditya A. Guru, 16, used whole exome sequencing (WES), an innovative genetic-screening technology, to find the mutation.
-
May 4, 2016
ARVO 2016: Emerging Drug Targets Toxic Build-Up in Stargardt Disease
In August 2015, the biotech company Alkeus launched a multi-center TEASE Phase II clinical trial for the drug ALK-001.
-
May 2, 2016
ARVO 2016: ProgSTAR, FFB-CRI's Stargardt Disease Patient Study, Highlighted
When the study and the reports are completed, the ProgSTAR database will be made available to researchers and companies developing therapies.
-
Apr 28, 2016
ARVO 2016: Choroideremia Gene Therapy in Clinical Trial Continues to Perform Well
Five of six patients in NightStaRx’s choroideremia gene-therapy trial continue to benefit from the treatment.